Dr. Reddy’s Laboratories (NYSE:RDY) Announces Quarterly Earnings Results

Dr. Reddy’s Laboratories (NYSE:RDY) announced its quarterly earnings data on Thursday. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.19 by $0.01, Zacks reports. Dr. Reddy’s Laboratories had a net margin of 17.81% and a return on equity of 18.53%.

Dr. Reddy’s Laboratories Price Performance

Shares of Dr. Reddy’s Laboratories stock traded down $0.78 during trading hours on Thursday, reaching $14.32. 674,242 shares of the company’s stock were exchanged, compared to its average volume of 2,212,194. Dr. Reddy’s Laboratories has a 1 year low of $13.61 and a 1 year high of $16.89. The company has a market capitalization of $11.95 billion, a P/E ratio of 22.87 and a beta of 0.51. The business has a fifty day moving average of $14.87 and a two-hundred day moving average of $15.54. The company has a quick ratio of 1.36, a current ratio of 1.92 and a debt-to-equity ratio of 0.02.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Nomura cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th. StockNews.com lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th. Finally, Barclays cut their price target on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.